Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease caused by scarring of the lung tissue. It’s classed as an interstitial lung disease and is very rare. While there is no definitive cause for IPF, there are many reasons why a person may be more likely to develop the…
Understanding the Facts of Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic lung condition which has a devastating effect on the lives of patients and their loved ones. In this film from the Canadian Pulmonary Fibrosis Foundation shared in 2014, we hear from the some of the people who have been directly affected by…
Last week I shared how important it is to make friends with your emotions, especially as a pulmonary fibrosis patient. I’ve been wading through a boatload of very difficult emotions since being diagnosed with pulmonary fibrosis two and a half…
Jordan Howard, the lead rusher for the Chicago Bears, is now auctioning his game-day Dec. 4 cleats in the NFL’s inaugural My Cause, My Cleats campaign to support the Pulmonary Fibrosis Foundation (PFF) and the pulmonary fibrosis (PF) community. The auction is open until Dec. 18, and the public can bid on…
Esbriet (pirfenidone) is an anti-inflammatory and anti-fibrotic drug which has been found to be effective in slowing down the rate of fibrosis in the lung tissue of patients with pulmonary fibrosis (PF). But which PF patients would benefit most from the drug? Esbriet may prevent acute flares in…
Although previously limited to the pulmonary system, new research suggests that acute exacerbations in idiopathic pulmonary fibrosis (IPF) also involve multiple organ systems. Moreover, two genes, scavenger receptor A (SRA) and TNF-α, are thought to play a role in mediating this systemic tissue damage. Acute exacerbations is the all-encompassing term…
It’s no surprise that sometimes people say things they don’t want to–or mean to. Especially when they’re talking to someone with a disease like pulmonary fibrosis (PF), that is not fully understood by those who don’t live with it. To help you learn more about what you shouldn’t say to…
Promedior, a biotechnology company that focuses on anti-tissue-scarring therapies, has lined up the patients it needs for two Phase 2 studies of PRM-151, an anti-scarring agent it is evaluating for the treatment of idiopathic pulmonary fibrosis (IPF) and myelofibrosis. “We believe attaining these (patient) enrollment milestones speaks to both the…
In this video from Boehringer Ingelheim Idiopathic Pulmonary Fibrosis shared in September 2014, Dr. Luca Richeldi from the Center for Rare Lung Diseases at the University of Modena and Reggio Emilia in Italy, talks about the progression of idiopathic pulmonary fibrosis (IPF) and the quality of life patients…
Differences in the expression of small RNAs, called microRNAs, which may be useful for identifying patients with idiopathic pulmonary fibrosis (IPF) at risk of an acute flare. The study, “Plasma microRNAs are associated with acute exacerbation in idiopathic pulmonary fibrosis,” was published in the journal Diagnostic Pathology. An acute IPF…
